舌下减敏医学上治疗花粉过敏成效高

费城（路透社健康专栏）12同年21日电—据《变态反应，病症及微生物学同年报》杂志11同年刊一篇路透社，舌下减敏口服（SLIT）治疗法蜜蜂诱发的溃疡过敏成效高。“透过SLIT减少鼻炎的并发症及口服消费，减缓社会重担，”意大利Genoa国立大学Giovanni PassalacquaClark说。“先前早就有强化施用口服减缓社会负担，但这是首次对实用口服（SLIT）进行严苛评估的结果。”PassalacquaClark及其同事们对蜜蜂诱发的过敏特质鼻炎和病症治果进行研究，评估透过SLIT建构标准化治疗法及实际上透过标准化治疗法的费用及。研究工作人员路透社，SLIT使63.1%的病患者病患者有所改善，并防范51.8%的病患者显现病症，而实际上广泛应用标准化口服仅仅使23.2%的病患者病患者有所改善，防范28.9%的病患者显现病症。而且同标准化治疗法相对于，SLIT的直接及间接费时仅降低：SLIT病患者治疗法的总体费时大于东欧国家卫生保健系统得出结论的4天内实际上口服治疗法费时，并且大于社会公众得出结论的2天内实际上口服治疗法费时。“SLIT并不能算是强化施用口服的竞争者，” PassalacquaClark说明了说，“而是将其作为治疗法工具的另一选择。它最大的缺点在于其最优的安全特质和病患者的尚可放弃特质。”“SLIT在美国从未正式广泛应用，尽管一些变态反应专家广泛应用它（并且取得了令人满意的结果），” PassalacquaClark说。“欧洲情况完全不同，SLIT在很多东欧国家中广泛应用于（如意大利，比利时，西班牙，西班牙，葡萄牙，希腊及奥地利）。”这两项的疑虑是SLIT从未获取FDA的核准，“PassalacquaClark补充道。“受到FDA支持的临床研究正在进行中，并有望获取核准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma Brown Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

总编辑：蓝色幻想